Boston Scientific Announces Schedule for Cardiostim World Congress
NATICK, Mass., June 11 /PRNewswire-FirstCall/ -- Boston
Scientific Corporation (NYSE:BSX) today announced the schedule of the
Company's key events and sponsored research at the 17th Cardiostim
World Congress, June 16 - 19 in Nice, France.
(All times are local; all events take place in the Nice
Acropolis Convention Center unless otherwise indicated.)
Sessions related to Boston Scientific's landmark MADIT-CRT heart
failure trial:
MADIT-CRT is the world's largest randomized study of New York
Heart Association (NYHA) Class I and II patients(1), with more than
1,800 patients enrolled at 110 centers worldwide. Results of the
MADIT-CRT trial were published in the October 2009 issue of the New
England Journal of Medicine. Boston Scientific currently has an
application under review with the U.S. Food and Drug Administration
(FDA) for the expansion of its CRT-D indication to include
high-risk(2) NYHA Class I and II patients with Left Bundle Branch
Block.
-- Results of MADIT-CRT Trial: Data on QRS Duration, Gender and Echo.
Arthur Moss, M.D., Principal Investigator of the MADIT-CRT trial, will
present results on June 16, 9:00 - 9:30 a.m. during Session 12 in Room
3.2.
-- CRT-D Effectiveness by QRS Duration and Morphology in MADIT-CRT
Patients. Dr. Moss will present results on June 16, 2:45 - 3:00 p.m.
during Session 46 in Room 1.2.
-- MADIT-CRT: Who are the Super Responders to Cardiac Resynchronization
Therapy? Dr. Moss will present results on June 16, 5:00 - 5:15 p.m.
during Session 64 in Room 2.6.
-- Boston Scientific Symposium: From Mirowski to MADIT-CRT: 30 years - Is
Today's Technology Fulfilling Needs of Indicated Patients? Dr. Moss
and Philippe Mabo, M.D., will chair a discussion on device therapy,
clinical trials and physician practice on June 17, 11:00 a.m. - 12:30
p.m. during Session 112 in Room 3.2.
-- Predictors of Outcome to Preventive Cardiac Resynchronization Therapy
in MADIT-CRT. Dr. Moss will present results on June 18, 2:00 - 2:15
p.m. during Session 205 in Room 1.1.
-- MADIT-CRT: Cardiac Resynchronization Therapy Reduces All-Cause
Mortality in Females. Results will be featured on June 18, 2:00 -
5:30 p.m. during Session 216/P in the Poster Area on Level 3.
Sessions related to Boston Scientific's ALTITUDE clinical science program:
The ALTITUDE clinical science program analyzes comprehensive
data from the Company's LATITUDE® Patient Management system.
The ALTITUDE program enhances understanding of device therapy,
outcomes and disease progression. The LATITUDE system allows
physicians to conduct remote follow-up of implantable cardiac
device patients to monitor specific device information and heart
health status. The system can also detect clinical events between
scheduled visits and send data directly to physicians.
-- Tachycardia Detection Programming and Shock Incidence in the ALTITUDE
Study. F. Roosevelt Gilliam, M.D., will present results on June 17,
10:15 - 10:30 a.m. during Session 86 in Room 1.2.
-- Noise and Oversensing-Related Inappropriate ICD Shocks Diagnosed with
Remote Monitoring: The ALTITUDE EGM Study. Samuel Asirvatham, M.D.,
will present results on June 17, 10:00 - 10:15 a.m. during Session 86
in Room 1.2.
Other activities and sessions of interest:
-- Boston Scientific Symposium: Applications and Uses of Different
Ablation Catheter Tips. Serge Boveda, M.D., and Jose Guerra, M.D.,
will chair a discussion on ablation clinical experience on June 16,
2:00 - 3:30 p.m. during Session 47 in Room 1.3.
-- The Jacques Mugica Conference. Kenneth Stein, M.D., Chief Medical
Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular
Group will co-chair the Jacques Mugica Conference on June 18, 4:00 -
5:30 p.m. during Session 235 in Room 3.5. Dr. Stein is also a
featured speaker during this session and will deliver a presentation
titled "A Multi-Sensor Approach to the Early Identification of Heart
Failure Decompensation: Building a Better Mousetrap."
Boston Scientific will present its latest cardiac rhythm
management and electrophysiology products at booths #D16 and
D8.
Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad
range of interventional medical specialties. For more information,
please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding clinical trials,
scientific activities, product performance, competitive offerings
and growth strategies. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions;
and, future business decisions made by us and our competitors. All
of these factors are difficult or impossible to predict accurately
and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A - Risk
Factors in our most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission, which we may update in Part
II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we
have filed or will file hereafter. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statements to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements. This
cautionary statement is applicable to all forward-looking
statements contained in this document.
(1) The NYHA clinical classifications of heart failure rank
patients as Class I-II-III-IV, according to the degree of symptoms
or functional limits, from asymptomatic to bed ridden. MADIT-CRT
patients are asymptomatic or mildly symptomatic, NYHA Class I
(ischemic) and Class II (ischemic and non-ischemic).
(2) High-risk is defined as QRS width greater than or equal to
130 milliseconds with Left Ventricular Ejection Fraction less than
or equal to 30% and Left Bundle Branch Block (LBBB). LBBB is a
condition in which the activation of the left ventricle is delayed.
As a result, portions of the left ventricle contract later than the
rest of the left ventricle and right ventricle, reducing the
heart's pumping ability.
CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation
David Knutson
651-582-6574 (office)
651-260-8288 (mobile)
Media Relations
Boston Scientific Corporation
Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation
Source: Boston Scientific Corporation
CONTACT: Media Relations, Paul Donovan, +1-508-650-8541
(office), or
+1-508-667-5165 (mobile), or David Knutson, +1-651-582-6574
(office), or
+1-651-260-8288 (mobile), or Investor Relations, Larry
Neumann,
+1-508-650-8696 (office), all of Boston Scientific
Corporation
Web Site: http://www.bostonscientific.com/
Posted: June 2010
